{"disease":{"id":"objective-response-rate-orr","name":"objective response rate orr"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03336554","title":"Epigenetic Biomarker for Osteosarcoma","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05582109","title":"Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}